コレラワクチン市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、製品別、流通チャネル別、地域別、競合別、2020～2030年

コレラワクチンの世界市場は、2024年には9,732万米ドルと評価され、予測期間中のCAGRは9.32%で、2030年には1億6,650万米ドルに達すると予測されています。

世界のコレラワクチン市場は、特に衛生状態が悪く、清潔な水へのアクセスが限られている地域でのコレラ発生頻度の上昇など、いくつかの要因によって牽引されています。気候変動や洪水などの自然災害、進行中の紛争は、コレラ病の蔓延をさらに助長しています。有効性が向上し、予防効果が長期間持続し、単回投与レジメンのような簡便な投与方法を備えた、より効果的なワクチンの開発は、市場の需要を押し上げています。ワクチン接種プログラムに資金を提供する政府や国際機関の支援は、世界のコレラ対策への取り組みを加速させるのに役立っています。世界の旅行による人の移動の増加もまた、疾病伝播のリスクを高め、コレラ発生を予防するためのワクチン接種の必要性をさらに高めています。

市場促進要因

コレラ発生頻度の増加

主な市場課題

物流とサプライチェーンの障壁

主要市場動向

世界の旅行と移動の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のコレラワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（全細胞コレラ菌、O1組換えBサブユニット、殺菌経口O1とO139）
  • 製品別（Vaxchora、Dukoral、Shanchol、その他）
  • 流通チャネル別（病院薬局、小売薬局、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のコレラワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のコレラワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のコレラワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のコレラワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのコレラワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収（ある場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Valneva SE
• Sanofi S.A.
• Emergent BioSolutions Inc.
• EuBiologics Co., Ltd.
• Shantha Biotechnics Limited
• Hilleman Laboratories Singapore Pte Ltd
• Astellas Pharma Inc.
• Incepta Pharmaceuticals Ltd.
• Bharat Biotech Ltd.
• Takeda Pharmaceutical Company Limited

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Cholera Vaccines Market was valued at USD 97.32 Million in 2024 and is expected to reach USD 166.50 Million by 2030 with a CAGR of 9.32% during the forecast period. The global cholera vaccine market is driven by several factors, including the rising frequency of cholera outbreaks, especially in regions with poor sanitation and limited access to clean water. Climate change and natural disasters, such as floods, as well as ongoing conflicts, further contribute to the spread of the disease. The development of more effective vaccines, with improved efficacy, longer-lasting protection, and convenient administration methods like single-dose regimens, has boosted market demand. The support of governments and international organizations funding vaccination programs helps accelerate efforts to combat cholera globally. The increased movement of people due to global travel also raises the risk of disease transmission, further driving the need for cholera vaccination to prevent outbreaks.

Key Market Drivers

Rising Frequency of Cholera Outbreaks

The increasing frequency of cholera outbreaks, particularly in regions with poor sanitation and inadequate healthcare infrastructure, is one of the primary factors driving the global cholera vaccine market. Cholera, a highly contagious waterborne disease caused by the Vibrio cholerae bacterium, spreads rapidly in environments where access to clean water is limited, and waste disposal practices are inadequate. Countries with low-income economies, especially those in Sub-Saharan Africa, parts of South Asia, and the Middle East, are seeing frequent cholera outbreaks that put populations at high risk. The World Health Organization (WHO) has released global cholera statistics for 2023, revealing an alarming rise in both cases and deaths. Reported cholera cases increased by 13%, while deaths surged by 71% compared to 2022. Over 4,000 people lost their lives to a disease that is preventable and easily treatable. A total of 45 countries reported cases in 2023, up from 44 the previous year and 35 in 2021. Notably, 38% of the reported cases were among children under five years of age. Cholera, an acute intestinal infection, spreads through contaminated food and water, with communities lacking proper sanitation being the most affected.

Key Market Challenges

Logistical and Supply Chain Barriers

One of the significant challenges to cholera vaccination campaigns is the logistical complexity of vaccine distribution. Many cholera-endemic regions are remote, with limited access to transportation infrastructure, making it difficult to distribute vaccines efficiently. Vaccines often require specific storage conditions, such as refrigeration, which may not be feasible in low-resource settings with inadequate cold chain infrastructure. Political instability, conflicts, and natural disasters can disrupt supply chains and delay vaccination efforts. In regions where cholera outbreaks occur in areas with poor infrastructure, vaccines may not reach the target populations in time to prevent widespread infection. The logistical challenges associated with transporting and storing vaccines in such conditions can limit the effectiveness of vaccination campaigns and prevent the full potential of cholera vaccination from being realized.

Key Market Trends

Increased Global Travel and Mobility

As global travel continues to increase, the risk of infectious diseases, including cholera, spreading across borders has grown. International travel and migration expose individuals to areas with active cholera outbreaks, raising the risk of the disease being transmitted across regions and even continents. Countries with high volumes of international travelers, such as those in Europe, the United States, and the Middle East, are increasingly emphasizing the importance of cholera vaccination to protect travelers and prevent the global spread of the disease. Governments and health authorities have recognized the need for pre-travel vaccinations, particularly for those visiting endemic regions, as a measure to reduce the likelihood of outbreaks in non-endemic areas. In August 2024, Bharat Biotech announced the launch of its new oral cholera vaccine, Hillchol, following successful results from phase 3 trials. Developed under a license from Singapore's Hilleman Laboratories, Bharat Biotech will produce the vaccine with an annual capacity of 200 million doses.

Key Market Players

• Valneva SE
• Sanofi S.A.
• Emergent BioSolutions Inc.
• EuBiologics Co., Ltd.
• Shantha Biotechnics Limited
• Hilleman Laboratories Singapore Pte Ltd
• Astellas Pharma Inc.
• Incepta Pharmaceuticals Ltd.
• Bharat Biotech Ltd.
• Takeda Pharmaceutical Company Limited

Report Scope:

In this report, the Global Cholera Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cholera Vaccines Market, By Type:

• Whole cell V. Cholerae O1 Recombinant With B-Subunit
• Killed Oral O1 & O139

Cholera Vaccines Market, By Product:

• Vaxchora
• Dukoral
• Shanchol
• Others

Cholera Vaccines Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Others

Cholera Vaccines Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cholera Vaccines Market.

Available Customizations:

Global Cholera Vaccines market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cholera Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Whole cell V. Cholerae O1 Recombinant With B-Subunit and Killed Oral O1 & O139)
  • 5.2.2. By Product (Vaxchora, Dukoral, Shanchol, and Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Cholera Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cholera Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Cholera Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Cholera Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Distribution Channel

7. Europe Cholera Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cholera Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Cholera Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy Cholera Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France Cholera Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Cholera Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Cholera Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cholera Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Cholera Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Cholera Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Cholera Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Cholera Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Distribution Channel

9. South America Cholera Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cholera Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Cholera Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Cholera Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Cholera Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cholera Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Cholera Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Cholera Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Valneva SE
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Sanofi S.A.
• 14.3. Emergent BioSolutions Inc.
• 14.4. EuBiologics Co., Ltd.
• 14.5. Shantha Biotechnics Limited
• 14.6. Hilleman Laboratories Singapore Pte Ltd
• 14.7. Astellas Pharma Inc.
• 14.8. Incepta Pharmaceuticals Ltd.
• 14.9. Bharat Biotech Ltd.
• 14.10. Takeda Pharmaceutical Company Limited

15. Strategic Recommendations

16. About Us & Disclaimer